JonesResearch downgraded Adaptimmune (ADAP) to Hold from Buy without a price target The firm cites the company’s capital overhang remaining as an ongoing concern for the downgrade. It awaits clarity on further financial strategies or partnerships for Adaptimmune.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADAP:
- Adaptimmune Therapeutics: Hold Rating Amid Financial Uncertainties and Strategic Challenges
- Adaptimmune price target lowered to $3 from $3.50 at H.C. Wainwright
- Adaptimmune Therapeutics: Balancing Positive Momentum with Strategic Pauses – A Hold Rating Analysis
- Adaptimmune price target lowered to $1.75 from $3 at Guggenheim
- Adaptimmune’s Earnings Call: TECELRA Success and Future Outlook